tiprankstipranks
CytomX Therapeutics Inc (DE:6C1)
FRANKFURT:6C1
Holding DE:6C1?
Track your performance easily

CytomX Therapeutics (6C1) Income Statement

3 Followers

CytomX Therapeutics Income Statement

Last quarter (Q3 2024), CytomX Therapeutics's total revenue was $33.43M, an increase of 26.71% from the same quarter last year. In Q3, CytomX Therapeutics's net income was $5.74M. See CytomX Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 126.62M$ 101.21M$ 53.16M$ 37.31M$ 100.36M$ 57.49M
Cost of Revenue
------
Gross Profit
$ 126.62M$ 101.21M$ 53.16M$ 37.31M$ 100.36M$ 57.49M
Operating Expense
$ 119.91M$ 107.70M$ 154.50M$ 153.35M$ 148.97M$ 168.38M
Operating Income
$ 6.71M$ -6.48M$ -101.33M$ -116.04M$ -48.60M$ -110.89M
Net Non Operating Interest Income Expense
$ 8.36M$ 9.84M$ 1.68M$ 255.00K$ 1.84M$ 8.37M
Other Income Expense
$ 29.00K$ -30.00K$ 340.00K$ 83.00K$ 27.00K$ 135.00K
Pretax Income
$ 15.06M$ 3.32M$ -99.32M$ -115.87M$ -46.80M$ -102.67M
Tax Provision
$ 1.23M$ 3.89M--$ -13.91M$ -427.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 13.83M$ -569.00K$ -99.32M$ -115.87M$ -64.82M$ -102.23M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 119.91M$ 107.70M$ 154.50M$ 153.35M$ 148.97M$ 168.38M
Net Income From Continuing And Discontinued Operation
$ 13.83M$ -569.00K$ -99.32M$ -115.87M$ -64.82M$ -102.24M
Normalized Income
$ 826.60K$ 2.63M-$ -91.54M--
Interest Expense
------
EBIT
$ 10.37M$ -6.48M$ -101.33M$ -116.04M$ -80.54M$ -102.67M
EBITDA
$ 14.07M$ -4.31M$ -98.89M$ -113.34M$ -77.97M$ -102.29M
Currency in USD

CytomX Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis